Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | HRH1 | P35367 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152281 | 0.90 | CYP2D6 (0.53) | GRM2DRD2CYP2D6HRH1DRD3 | |
| SCHEMBL4154027 | 0.88 | CYP2D6 (0.52) | GRM2DRD2CYP2D6HRH1DRD3 | |
| SCHEMBL20281673 | 0.85 | PDE2A (0.58) | GRM2DRD2DRD3DRD4PDE2A | |
| SCHEMBL4153083 | 0.85 | CCR3 (0.43) | CYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL4139191 | 0.83 | GRM2 (0.55) | GRM2DRD2CYP2D6HRH1DRD3 | |
| SCHEMBL8228158 | 0.79 | GRM2 (0.54) | GRM2DRD2CYP2D6DRD3DRD4 | |
| SCHEMBL20281857 | 0.79 | GRM2 (0.56) | GRM2DRD2DRD3DRD4PDE2A | |
| SCHEMBL4146825 | 0.78 | GRM2 (0.70) | GRM2DRD2DRD3DRD4 | |
| SCHEMBL4152111 | 0.77 | GRM2 (0.58) | GRM2DRD2DRD3DRD4 | |
| SCHEMBL4142202 | 0.76 | GRM2 (0.82) | GRM2DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-2004613-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007115077-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | claimed |
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| EP-3810612-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112292381-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20200079766-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2020-03-12 | — | — | US | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| EP-3555087-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109202-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| WO-2007115077-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GRM2 761/4885DRD2 4676/4885CYP2D6 4092/4885 |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885DRD2 101/4885CYP2D6 1251/4885 |
| US-20200079766-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | OGA, OGT, PSEN1 | GRM2 363/4885DRD2 4669/4885CYP2D6 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.